Sativex (nabiximols) is a cannabis-based oral spray. It is the first drug made with ingredients extracted from the cannabis plant. Sativex contains an equal 1:1 ratio of THC and CBD. It also contains a variety of other compounds found in cannabis.
Sativex is administered as a mouth spray. The active ingredients are absorbed through the inner linings of the mouth. As a result, it enters the bloodstream quicker than other oral cannabinoid preparations.
Sativex was developed by a UK company called GW Pharmaceuticals. The company received an exclusive, government-issued license in 1998 to cultivate cannabis for research purposes.
Sativex is sold in various countries under marketing arrangements with Bayer, Novartis, Ipsen, Almirall and Otsuka Pharmaceuticals.
2007 – Approved in Canada for cancer pain
2010 – Approved and launched in UK for MS spasticity. Approved in Canada for MS spasticity
2011 – Launched in Germany, Spain and Denmark for MS spasticity
2012 – Launched in Norway and Israel for MS spasticity
2013 – Launched in Austria, Sweden, Italy and Poland for MS spasticity. Moved from Schedule 1 to Schedule 4 (UK)
2014 – Granted FDA Fast Track designation for cancer pain
Read More: 7 Things You Need To Know About Sativex